AGP Executive Report
Last update: an hour agoGLP-1 Deal Watch: Novo Nordisk is paying Hengrui Pharma up to $2.6B for HRS-1596, a once-weekly oral GLP-1/GIP dual agonist candidate; Hengrui already has Phase 1 trials in China for weight management and type 2 diabetes, raising hopes for a more convenient obesity option. AI for Mental Health: The FDA and other groups are pushing chatbot mental-health benchmarking, with China’s broader AI rollout increasingly paired with regulation—an approach that could shape how AI therapy tools are approved and kept safe for kids. Robots Move Into Retail: China’s robot store boom is bringing humanoids and other AI products into malls and streets, signaling a shift from demos to commercialization. Health Safety Case: Doctors in China report fat embolism syndrome after a rare “digital crush” injury, urging clinicians to watch for breathing trouble even when fractures seem minor. Research & Tech: Chinese scientists report perovskite solar cells that generate electricity underwater, pointing to new marine energy uses. Public Health Surveillance: WHO calls for stronger border health surveillance to curb cross-border infectious disease spread. Bear Welfare: A sanctuary in Vietnam received a private concert for 150 rescued moon bears, spotlighting the cruelty of bear bile extraction tied to traditional medicines.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
